Joensuu H, Fraser J, Wildiers H, et al. A randomized phase III study of adjuvant trastuzumab for a duration of 9 weeks versus 1 year, combined with adjuvant taxane-anthracycline chemotherapy, for early HER2-positive breast cancer (the SOLD study). SABCS 2017, GS3-04.
Overleving Europese adolescenten en jongvolwassenen met kanker is verbeterd
apr 2024 | Leukemie, Neuro-oncologie